Table 1.
Clinical trials reporting single-agent liposomal doxorubicin therapy for refractory ovarian cancer, with dosage, response, survival, and toxicity information
| Ovarian cancer | Patients (n) | Dose/4 weeks | ORR | PFS/OS months | Grade 3+4 toxicity | ||
|---|---|---|---|---|---|---|---|
| Berger et al1 | Lipodox® | Recurrent | 18 | 30 mg/m2 | 0 | 2.8/NR | Neutropenia 5.6% |
| Lin et al6 | Lipo-Dox® | CDDP-resistant and paclitaxel-resistant | 18 | 40 mg/m2 | 27.8%, three CR, two PR | 3.5/12 | 0 |
| Chou et al4 | Lipo-Dox | Resistant/refractory | 29 | 45 mg/m2 | 23%, one CR, five PR | 5.4/13.8 | Neutropenia 12% |
Abbreviations: CR, complete response; PR, partial response; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; NR, not reached; CDDP, diamminedichloroplatinum(II).